| 词条 | Ibandronic acid | ||||||||||||||||
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461936767 | IUPAC_name = {1-Hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid) | image = Ibandronate.svg | tradename = | Drugs.com = {{drugs.com|international|ibandronic-acid}} | licence_EU = yes | licence_US = ibandronate_sodium | pregnancy_US = C | legal_status = Rx-only | routes_of_administration = Oral, intravenous | bioavailability = 0.6% | protein_bound = 90.9 to 99.5% (concentration-dependent) | metabolism = Nil | elimination_half-life = 10 to 60 hours | excretion = Renal | IUPHAR_ligand = 3059 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 114084-78-5 | ATC_prefix = M05 | ATC_suffix = BA06 | PubChem = 60852 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB00710 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 54839 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = UMD7G2653W | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D08056 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 997 | C=9 | H=23 | N=1 | O=7 | P=2 | molecular_weight = 319.229 g/mol | smiles = O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = MPBVHIBUJCELCL-UHFFFAOYSA-N }} Ibandronic acid or ibandronate sodium is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.[1] It may also be used to treat hypercalcemia (elevated blood calcium levels). It was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996.[2] Medical usesIbandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.[3] In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug. Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.[4] Adverse effectsIn 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain.[5] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. [6] The drug also has been associated with osteonecrosis of the jaw, relatively rare but serious condition.[7]Pharmacology
Brand namesIbandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia, Bandrone in India, Ibandrix in Ecuador, Adronil in Pakistan, Bondrova in Bangladesh and Bonprove in Egypt. References1. ^{{cite journal |author=Bauss F, Schimmer RC |title=Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis |journal=Therapeutics and Clinical Risk Management |volume=2 |issue=1 |pages=3–18 |date=March 2006 |pmid=18360577 |pmc=1661644 |doi= |url=}} 2. ^{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=523 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA523 |language=en}} 3. ^{{cite web|title=boniva|url=https://www.drugs.com/monograph/boniva.html|work=The American Society of Health-System Pharmacists|accessdate=3 April 2011}} 4. ^{{cite journal |author=Sittig HB |title=Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate |journal=Onkologie |volume=35 |issue=6 |pages=380–7 |year=2012 |pmid=22722461 |doi=10.1159/000338947 |url=}} 5. ^{{Cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm|title=Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)|publisher=U.S. Food and Drug Administration|accessdate=27 October 2010}} 6. ^{{Cite web|url=http://www.asbmr.org/about/pressreleases/detail.aspx?cid=a68f2b70-a117-4094-9f6f-b5993c6a6149|title=Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term |publisher=Journal of Bone and Mineral Research=27 October 2010}} 7. ^{{Cite web|url=https://nos.org.uk/media/1593/k-drug-treatments-for-osteoporosis-osteonecrosis-of-the-jaw-onj-_.pdf|title=Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis|last=|first=|date=|website=nos.org.uk|publisher=The National Osteoporosis Society|archive-url=|archive-date=|dead-url=|access-date=}} 8. ^{{Cite book|url=https://www.worldcat.org/oclc/868299888|title=Essentials of medical pharmacology|last=D.,|first=Tripathi, K.|isbn=9789350259375|edition= Seventh|location=New Delhi|oclc=868299888}} External links
6 : Amines|Bisphosphonates|Farnesyl pyrophosphate synthase inhibitors|Hoffmann-La Roche|Genentech|GlaxoSmithKline brands |
||||||||||||||||
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。